Candidate biomarkers in narcolepsy in H1N1-vaccinated cohorts: A proteomic and transcriptomic study.

Muataz S Lafta¹, Aleksandr V Sokolov¹, Mattis Kitok², Shala G Berntsson², Valter Niemelä², Anne Huutoniemi³, Markku Partinen³, Helgi B Schiöth¹, Anne-Marie Landtblom⁴

¹Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.

²Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.

³Helsinki Sleep Clinic, Vital Research Centre, and Department of Neurology, University of Helsinki, Finland.

⁴Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Electronic address: anne-marie.landtblom@neuro.uu.se.

PubMed DOI

Abstract

Narcolepsy is a rare neurological disorder caused by the loss of function in neurons producing orexin or hypocretins, disrupting the sleep-wake cycle. In Sweden and Finland approximately 800 patients developed narcolepsy after swine flu (H1N1) vaccination between 2009 and 2010, probably as an autoimmune side effect. The vaccinated cohorts are of great scientific interest owing to their specific ex…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.